Table 3

Markers of angiogenesis

Intermittent HBO

Daily HBO

Tumor

Stroma

Tumor

Stroma

Genes

Gene name

Fold

change

Fold

change

Fold

change

Fold change


Anti-Angiogenic


Serpinb5

Serine (or cysteine) peptidase inhibitor, clade B, member 5

3.4

1.6

5.0

NS

Csta

Cystatin A

0.1

NS

NS

NS

Thbs1

Thrombospondin1

0.5

0.5

NS

NS

Thbs2

Thrombospondin2

NS

2.7

NS

2.5

Thbs3

Thrombospondin3

NS

NS

0.7

NS

Thbs4

Thrombospondin4

0.8

NS

NS

NS


Pro-angiogenic


HIF1a

Hypoxia-inducible factor 1, alpha

NS

NS

0.7

NS

Pecam1

Platlet/endothelial cell adhesion molecule 1

0.9

0.5

0.6

NS

Vwf

Von Willebrand factor homolog

0.7

0.3

NS

0.6

Vegfa

Vascular endothelial growth factor A

0.5

0.5

NS

1.4

Vegfb

Vascular endothelial growth factor B

NS

NS

0.7

NS

Vegfc

Vascular endothelial growth factor C

0.6

NS

0.5

NS

Pdgfa

Platelet derived growth factor, alpha

0.8

0.7

NS

NS

Pdgfb

Platelet derived growth factor, b

1.2

0.7

NS

NS

Pdgfra

Platelet derived growth factor receptor, alpha

0.7

2.3

0.5

2.1

Tgfb1

Transforming growth factor, beta 1

NS

0.8

0.8

NS

Il6

Interleukin 6

0.5

NS

NS

0.3

Fgfr1

Fibroblast growth factor receptor 1

0.9

NS

NS

NS

Fgfr3

Fibroblast growth factor receptor 3

0.7

NS

0.7

NS

Egfr

Epidermal growth factor receptor

0.5

NS

0.5

2.7

Serpinb2

Serine (or cysteine) peptidase inhibitor, clade B, member 2

0.6

NS

NS

0.5


Displayed results are fold change of gene expression in intermittent and daily hyperbaric oxygen (HBO) treated tumors cells compared to untreated control tumor cells, and intermittent and daily HBO treated stromal cells compared to untreated stromal cells. A positive fold change indicates increased expression after treatment. FDR < 0.05%, NS = not significant

Moen et al. BMC Cancer 2012 12:21   doi:10.1186/1471-2407-12-21

Open Data